146 related articles for article (PubMed ID: 24672123)
21. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients.
Akizawa T; Koshikawa S; Iwasaki M;
Ther Apher Dial; 2007 Jun; 11(3):220-6. PubMed ID: 17498005
[TBL] [Abstract][Full Text] [Related]
22. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
[TBL] [Abstract][Full Text] [Related]
23. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
24. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
Ling B; Walczyk M; Agarwal A; Carroll W; Liu W; Brenner R
Clin Nephrol; 2005 May; 63(5):327-34. PubMed ID: 15909591
[TBL] [Abstract][Full Text] [Related]
25. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R
Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932
[TBL] [Abstract][Full Text] [Related]
26. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C
Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
[TBL] [Abstract][Full Text] [Related]
27. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
28. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
Macdougall IC; Matcham J; Gray SJ;
Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
[TBL] [Abstract][Full Text] [Related]
29. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C
Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
[TBL] [Abstract][Full Text] [Related]
30. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
31. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
32. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients.
Kim CD; Park SH; Kim DJ; Park JW; Do JY; Shin SK; Kim BS; Seo JJ; Kim YL
Nephrology (Carlton); 2009 Aug; 14(5):482-7. PubMed ID: 19298639
[TBL] [Abstract][Full Text] [Related]
34. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
[TBL] [Abstract][Full Text] [Related]
35. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
36. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Glaspy JA; Jadeja JS; Justice G; Fleishman A; Rossi G; Colowick AB
Cancer; 2003 Mar; 97(5):1312-20. PubMed ID: 12599240
[TBL] [Abstract][Full Text] [Related]
37. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
38. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
39. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
[TBL] [Abstract][Full Text] [Related]
40. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]